XAGE on OTC
Longevity Health Holdings, Inc.
American soap company that raised $6 million in 2026 (SEC Form D). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
Compare with Park Ha Biological Technology Co., Ltd., Meiwu Technology Co Ltd or Orion Bliss Corp., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue43¢$818.1K
- Research and development41¢$788.9K
- Other costs13¢$251.4K
- Interest1¢$18.2K
- Income tax2¢$36.3K
Out of $1.9M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Gross sales | $2.2M | $90.8K |
| Discounts and allowances | -$239.5K | -$40.5K |
| Net sales | $1.9M | $50.3K |
| Cost of sales | $818.1K | $6.4K |
| Gross profit | $1.1M | $44.0K |
| Selling and marketing | $1.4M | $189.3K |
| Research and development | $788.9K | $1.1M |
| General and administrative | $5.9M | $3.7M |
| Depreciation and amortization of intangible assets | $78.7K | $83.5K |
| Total operating expenses | $8.2M | $5.0M |
| Loss from operations | -$7.1M | -$5.0M |
| Other income | $168.1K | $44.8K |
| Interest expense | -$18.2K | -$29.5K |
| Change in fair value of earnout liabilities | $149.6K | $0 |
| Inventory write-down | -$61.0K | $0 |
| Amortization of debt discount | $0 | -$19.5K |
| Loss on forward purchase agreement | $0 | -$5.7M |
| Loss on lease termination | $0 | -$44.6K |
| Total other income (expense) | $238.6K | -$5.7M |
| Loss from continuing operations before income taxes | -$6.9M | -$10.7M |
| Income tax expense (benefit) | $36.3K | -$97.3K |
| Loss from continuing operations | -$6.9M | -$10.7M |
| Loss from discontinued operations, net of tax | $0 | -$1.2M |
| Gain on sale of discontinued operations | $0 | $1.4M |
| Net loss | -$6.9M | -$10.4M |
| Net loss from continuing operations - basic | -$5 | -$15 |
| Discontinued operations, net of tax - basic | $0 | $0 |
| Net loss per common share - basic | -$4.83 | -$14.56 |
| Net loss from continuing operations - diluted | -$5 | -$15 |
| Discontinued operations, net of tax - diluted | $0 | $0 |
| Net loss per common share - diluted | -$4.83 | -$14.56 |
| Weighted average of common shares outstanding , Basic | 1.4M shares | 712.1K shares |
| Weighted average of common shares outstanding, Diluted | 1.4M shares | 712.1K shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.3
| Period ending | 2025-12-31 | 2025-04-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $706.7K | $157.1K | ||
| Accounts receivable | $36.5K | $4.1K | ||
| Inventory | $963.0K | $108.7K | ||
| Prepaid expenses | $243.8K | $297.5K | ||
| Deferred offering costs | $0 | $86.3K | ||
| Income taxes receivable | $0 | $301.8K | ||
| Total current assets | $2.0M | $955.6K | ||
| Operating lease right of use asset | $300.2K | $384.9K | ||
| Property and equipment, net of accumulated depreciation of $775,783 and $701,655, respectively | $101.6K | $113.9K | ||
| Intangible assets, net of accumulated amortization of $55,652 and $51,105, respectively | $15.1K | $19.6K | ||
| Total assets | $2.4M | $1.5M | ||
| Accounts payable | $4.5M | $4.1M | ||
| Accrued interest | $1.2M | $1.2M | ||
| Accrued expenses and other liabilities | $1.8M | $313.7K | ||
| Loans payable | $189.9K | $241.2K | ||
| Consideration payable | $67.7K | $0 | ||
| Earnout liabilities | $49.2K | $0 | ||
| Operating lease liability | $95.2K | $87.9K | ||
| Total current liabilities | $7.9M | $5.9M | ||
| Earnout payable, net of current portion | $102.9K | $0 | ||
| Operating lease liability, net of current portion | $214.7K | $309.9K | ||
| Total liabilities | $8.2M | $6.2M | ||
| Series A convertible voting preferred stock, $0.0001 par value; 4,243 shares authorized, -0- shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value, 250,000,000 shares authorized, and 1,781,738 and 696,969 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $178 | $70 | ||
| Additional paid-in capital | $69.9M | $64.2M | ||
| Accumulated deficit | -$75.8M | -$68.9M | ||
| Total stockholders' deficit | -$5.9M | -$4.7M | $24.7M | |
| Total liabilities and stockholders' deficit | $2.4M | $1.5M | ||
| Accumulated depreciation on property plant and equipment | $775.8K | $701.7K | ||
| Finite lived intangible asset accumulated depreciation | $55.7K | $51.1K | ||
| Preferred stock shares authorized | 20.0M shares | |||
| Common stock par or stated value per share | $0.00 | $0.00 | $0.00 | |
| Common stock shares authorized | 250.0M shares | 250.0M shares | ||
| Common stock shares issued | 1.8M shares | 697.0K shares | ||
| Common stock shares outstanding | 1.8M shares | 697.0K shares |
| Period ending | 2025-12-31 | 2025-04-30 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $706.7K | $157.1K | ||
| Accounts receivable | $36.5K | $4.1K | ||
| Inventory | $963.0K | $108.7K | ||
| Prepaid expenses | $243.8K | $297.5K | ||
| Deferred offering costs | $0 | $86.3K | ||
| Income taxes receivable | $0 | $301.8K | ||
| Total current assets | $2.0M | $955.6K | ||
| Operating lease right of use asset | $300.2K | $384.9K | ||
| Property and equipment, net of accumulated depreciation of $775,783 and $701,655, respectively | $101.6K | $113.9K | ||
| Intangible assets, net of accumulated amortization of $55,652 and $51,105, respectively | $15.1K | $19.6K | ||
| Total assets | $2.4M | $1.5M | ||
| Accounts payable | $4.5M | $4.1M | ||
| Accrued interest | $1.2M | $1.2M | ||
| Accrued expenses and other liabilities | $1.8M | $313.7K | ||
| Loans payable | $189.9K | $241.2K | ||
| Consideration payable | $67.7K | $0 | ||
| Earnout liabilities | $49.2K | $0 | ||
| Operating lease liability | $95.2K | $87.9K | ||
| Total current liabilities | $7.9M | $5.9M | ||
| Earnout payable, net of current portion | $102.9K | $0 | ||
| Operating lease liability, net of current portion | $214.7K | $309.9K | ||
| Total liabilities | $8.2M | $6.2M | ||
| Series A convertible voting preferred stock, $0.0001 par value; 4,243 shares authorized, -0- shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $0 | $0 | ||
| Common stock, $0.0001 par value, 250,000,000 shares authorized, and 1,781,738 and 696,969 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $178 | $70 | ||
| Additional paid-in capital | $69.9M | $64.2M | ||
| Accumulated deficit | -$75.8M | -$68.9M | ||
| Total stockholders' deficit | -$5.9M | -$4.7M | $24.7M | |
| Total liabilities and stockholders' deficit | $2.4M | $1.5M | ||
| Accumulated depreciation on property plant and equipment | $775.8K | $701.7K | ||
| Finite lived intangible asset accumulated depreciation | $55.7K | $51.1K | ||
| Preferred stock shares authorized | 20.0M shares | |||
| Common stock par or stated value per share | $0.00 | $0.00 | $0.00 | |
| Common stock shares authorized | 250.0M shares | 250.0M shares | ||
| Common stock shares issued | 1.8M shares | 697.0K shares | ||
| Common stock shares outstanding | 1.8M shares | 697.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss from continuing operations | -$6.9M | -$10.7M |
| Loss from discontinued operations, net of tax | $0 | -$1.2M |
| Gain on sale of discontinued operations | $1.4M | |
| Gain on sale of discontinued operations | -$1.4M | |
| Stock-based compensation | $692.8K | $827.0K |
| Depreciation and amortization of intangible assets | $78.7K | $83.5K |
| Amortization of right of use assets | $136.4K | $113.8K |
| Change in fair value of earnout liabilities | -$149.6K | $0 |
| Inventory write-down | $61.0K | $0 |
| Amortization of debt discount | $0 | $19.5K |
| Loss on forward purchase agreement | $0 | $5.7M |
| Accounts receivable and other current assets | $44.2K | -$4.1K |
| Inventory | $370.9K | -$108.7K |
| Prepaid expenses | $537.7K | $959.5K |
| Income taxes receivable | $301.8K | -$97.3K |
| Assets available for sale | $4.7M | |
| Accounts payable | $126.9K | -$359.1K |
| Accrued expenses and other liabilities | $1.5M | -$1.3M |
| Lease liability | -$140.5K | -$117.0K |
| Liabilities available for sale | -$2.5M | |
| Net cash used in operating activities | -$3.3M | -$3.9M |
| Cash paid for Elevai Acquisition transaction costs | -$150.0K | |
| Purchases of property and equipment | -$14.2K | |
| Cash paid in AxoBio Disposition | -$748.8K | |
| Net cash used in investing activities | -$164.2K | -$748.8K |
| Proceeds from issuance of Common Stock, net of costs | $3.5M | $2.7M |
| Proceeds from exercise of Common Stock warrants | $1.0M | |
| Repayment of loans | -$440.7K | -$714.2K |
| Deferred offering costs | -$86.3K | |
| Net cash provided by financing activities | $4.0M | $1.9M |
| Net increase (decrease) in cash and cash equivalents | $549.6K | -$2.8M |
| Interest paid | $18.2K | $29.5K |
| Income taxes refunded | $265.6K | |
| Fair value of shares issued in Elevai Acquisition | $660.8K | |
| Consideration payable | $67.7K | |
| Earnout liabilities in Elevai Acquisition | $301.6K | |
| Insurance premium financing agreements | $389.5K | $495.7K |
| Fair value of shares received in AxoBio Disposition | $23.5M | |
| Net assets sold in AxoBio Disposition | $21.9M | |
| Common Stock issued in connection with conversion of Notes | $848.5K | |
| Decrease in right of use asset and lease liabilities related to termination of lease | $333.0K |
No quarter-by-quarter statement was filed.
Compare Longevity Health Holdings, Inc. with another company
Leadership
Who has led Longevity Health Holdings, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
- Chief executive officerJ. Ram Ajjarapu Apr 8, 2026 to now10
- Chief executive officerKendra Bracken-Ferguson Aug 8, 2024 to Apr 8, 202611
- Chief executive officerRandolph W. Hubbell Jul 18, 2023 to Aug 30, 202312
- Chief executive officerRajiv Shukla Jul 27, 2021 to Jul 18, 202313
- ChairRajiv Shukla Aug 31, 2023 to now14
- PresidentRandolph W. Hubbell Jul 18, 2023 to Aug 30, 202312
- Chief financial officerBryan J. Cassaday Nov 30, 2023 to now15
- Chief financial officerPatrick A. Sturgeon Jul 27, 2021 to Jul 27, 202116
Board members and other officers (16)
- Chief Quality OfficerDonna Godward Jul 18, 2023 to Jul 18, 202317
- VP, Clinical ServicesJanet Vargo Jul 18, 2023 to Jul 18, 202318
- Board memberJ. Ram Ajjarapu Apr 8, 2026 to now10
- Board memberJaime Garza Jul 18, 2023 to Jul 18, 202319
- Board memberKathryn Gregory Jul 18, 2023 to now20
- Board memberRandolph W. Hubbell Jul 18, 2023 to Aug 30, 202312
- Board memberRichard A. Upton Jul 18, 2023 to now21
- Board memberSteven Bariahtaris Jul 18, 2023 to Jul 18, 202322
- Board memberWilliam R. Newlin Jul 18, 2023 to Jul 18, 202323
- Board memberGilles Spenlehauer Dec 8, 2023 to now24
- Board memberPatrick A. Sturgeon Dec 8, 2023 to now25
- Board memberScott M. Frisch Dec 8, 2023 to now26
- Board memberDarlene T. Deremer Jul 27, 2021 to Jul 27, 202127
- Board memberEugene L. Podsiadlo Jul 27, 2021 to Jul 27, 202128
- Board memberRajiv Shukla Jul 27, 2021 to Jul 27, 202113
- Board memberWilliam Woodward Jul 27, 2021 to Jul 27, 202129
Named in SEC Form D filings
People the company listed in its private-offering notices.
Former names
Timeline
Filings
301 filings to the SEC since October 2021: 8 annual reports, 16 quarterly reports, 59 major events, 91 insider forms, 29 large holders, 4 private raises, 94 other. The latest 20:
- Sep 8, 2026424B3 EDGAR
- Sep 8, 20268-K EDGAR
- Sep 8, 2026424B3 EDGAR
- Sep 4, 20268-K EDGAR
- Aug 17, 2026424B3 EDGAR
- Aug 17, 20268-K EDGAR
- Aug 14, 2026424B3 EDGAR
- Aug 14, 2026424B3 EDGAR
- Aug 14, 202610-Q EDGAR
- Aug 14, 20268-K EDGAR
- Jun 4, 20268-K EDGAR
- May 15, 2026424B3 EDGAR
- May 15, 202610-Q EDGAR
- Apr 8, 2026SCHEDULE 13D EDGAR
- Apr 8, 20264 EDGAR
- Apr 8, 20263 EDGAR
- Mar 31, 2026424B3 EDGAR
- Mar 31, 202610-K EDGAR
- Mar 30, 2026D EDGAR
- Mar 17, 20268-K EDGAR
The 301 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
125 open-market trades by officers, directors and large owners since October 2021: 125 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Ajjarapu J. RamChief Executive Officer | Buy | 689,656 | $0.29 | $200.0K | Form 4 |
| Sep 13, 2024 | Upton Richard ADirector | Buy | 5,000 | $0.47 | $2.4K | Form 4 |
| Sep 10, 2024 | Cassaday Bryan J.Chief Financial Officer | Buy | 475 | $0.46 | $218 | Form 4 |
| Sep 6, 2024 | Spenlehauer GillesDirector | Buy | 1,009 | $0.51 | $515 | Form 4 |
| Sep 6, 2024 | Gregory KathrynDirector | Buy | 1,260 | $0.51 | $643 | Form 4 |
| Sep 6, 2024 | Sturgeon Patrick ADirector | Buy | 1,261 | $0.51 | $643 | Form 4 |
| Sep 6, 2024 | Frisch Scott M.Director | Buy | 1,009 | $0.51 | $515 | Form 4 |
| Aug 30, 2024 | Gregory KathrynDirector | Buy | 109 | $0.57 | $62 | Form 4 |
| Aug 30, 2024 | Frisch Scott M.Director | Buy | 87 | $0.57 | $50 | Form 4 |
| Aug 30, 2024 | Sturgeon Patrick ADirector | Buy | 109 | $0.57 | $62 | Form 4 |
| Aug 30, 2024 | Spenlehauer GillesDirector | Buy | 87 | $0.57 | $50 | Form 4 |
| Aug 29, 2024 | Sturgeon Patrick ADirector | Buy | 652 | $0.56 | $365 | Form 4 |
| Aug 29, 2024 | Gregory KathrynDirector | Buy | 652 | $0.56 | $365 | Form 4 |
| Aug 29, 2024 | Spenlehauer GillesDirector | Buy | 522 | $0.56 | $292 | Form 4 |
| Aug 29, 2024 | Frisch Scott M.Director | Buy | 522 | $0.56 | $292 | Form 4 |
| Aug 29, 2024 | Cassaday Bryan J.Chief Financial Officer | Buy | 1,000 | $0.57 | $570 | Form 4 |
| Aug 29, 2024 | Anderson David WDirector | Buy | 652 | $0.56 | $365 | Form 4 |
| Aug 28, 2024 | Sturgeon Patrick ADirector | Buy | 970 | $0.56 | $543 | Form 4 |
| Aug 28, 2024 | Gregory KathrynDirector | Buy | 1,084 | $0.56 | $607 | Form 4 |
| Aug 28, 2024 | Spenlehauer GillesDirector | Buy | 599 | $0.56 | $335 | Form 4 |
All 125 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- J. Ram AjjarapuSCHEDULE 13D, 1 filing Apr 8, 202632
- Newlin Investment Co 1, LLCSCHEDULE 13G/A, 3 filings Feb 6, 2024 to Feb 7, 202533
- METEORA CAPITAL, LLCSC 13G/A, 3 filings Feb 14, 2024 to Dec 6, 202434
- SANDSTONE Asset ManagementSC 13G/A, 3 filings Mar 21, 2023 to Apr 18, 202435
- Antara Capital LPSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202436
- BALYASNY ASSET MANAGEMENT L.P.SC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202437
- P SCHOENFELD ASSET MANAGEMENT LPSC 13G/A, 2 filings Feb 14, 2023 to Feb 14, 202438
- Sculptor Capital LPSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 202439
- OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC)SC 13G/A, 3 filings Feb 14, 2022 to Feb 12, 202440
- Linden Capital L.P.SC 13G/A, 3 filings Feb 3, 2022 to Feb 7, 202441
- INTEGRATED CORE STRATEGIES (US) LLCSC 13G/A, 2 filings Feb 6, 2023 to Feb 5, 202442
- Rajiv ShuklaSC 13G, 1 filing Nov 21, 202343
Money raised
Private offerings the company reported to the SEC on Form D.
- Mar 16, 2026Raised $200,000 in a private offering of equity Form D: 1 investor so far Form D
- Jan 16, 2025Raised $975,463 in a private offering of equity Form D: $1.1 million offered in all Form D
- Jan 2, 2025Raised $1.9 million in a private offering of equity Form D: $3.7 million offered in all Form D
- Apr 11, 2024Raised $3 million in a private offering of equity Form D: 19 investors so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| DRW Securities, LLC | 14,154 | $3.7K | 0.0% | No change |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14SEC EDGARRajiv Shukla, Chair
- 15
- 16
- 17SEC EDGARDonna Godward, Chief Quality Officer
- 18SEC EDGARJanet Vargo, VP, Clinical Services
- 19SEC EDGARJaime Garza, Board member
- 20SEC EDGARKathryn Gregory, Board member
- 21SEC EDGARRichard A. Upton, Board member
- 22SEC EDGARSteven Bariahtaris, Board member
- 23SEC EDGARWilliam R. Newlin, Board member
- 24SEC EDGARGilles Spenlehauer, Board member
- 25SEC EDGARPatrick A. Sturgeon, Board member
- 26SEC EDGARScott M. Frisch, Board member
- 27SEC EDGARDarlene T. Deremer, Board member
- 28SEC EDGAREugene L. Podsiadlo, Board member
- 29SEC EDGARWilliam Woodward, Board member
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43